Recruiting
An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab - CA013-004
Updated: 23 March, 2020 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Solid cancers that are advanced or have spread (for which alternative therapies were deemed not effective) - Eastern Cooperative Oncology Group (ECOG) 0-1 - Acceptable lab testing results - Allow biopsies Exclusion Criteria: - Central nervous system (CNS) tumors - Uncontrolled or significant cardiovascular diseases - Active or known autoimmune disease - Organ transplant Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
